ARS Pharmaceuticals, Inc. Other Assets
ARS Pharmaceuticals, Inc. (SPRY) had Other Assets of $2.96 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Prepaid Expense and Other Assets
us-gaap:OtherAssets · last filed 2026-08-13
- 2026-06-30: Other Assets $2.96M.
- 2026-03-31: Other Assets $2.65M.
- 2025-12-31: Other Assets $2.79M.
- 2025-09-30: Other Assets $2.92M.
| Period end | Other Assets |
|---|---|
| 2026-06-30 | $2.96M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.79M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $2.92M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.05M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.13M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.11M 10-K · filed 2026-03-09 |
| 2024-09-30 | $377.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $446.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $528.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $638.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $3.17M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.77M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.86M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.96M 10-K · filed 2024-03-21 |
| 2021-12-31 | $23.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |